

## EPIDEMIOLOGY

# Vaccine waning and mumps re-emergence in the United States

Joseph A. Lewnard<sup>1\*</sup> and Yonatan H. Grad<sup>2,3\*</sup>

After decades of declining mumps incidence amid widespread vaccination, the United States and other developed countries have experienced a resurgence in mumps cases over the last decade. Outbreaks affecting vaccinated individuals and communities with high vaccine coverage have prompted concerns about the effectiveness of the live attenuated vaccine currently in use. It is unclear whether immune protection wanes or whether the vaccine protects inadequately against currently circulating mumps virus lineages. Synthesizing data from six studies of mumps vaccine effectiveness, we estimated that vaccine-derived immune protection against mumps wanes on average 27 years (95% confidence interval, 16 to 51 years) after vaccination. After accounting for this waning, we found no evidence that the emergence of heterologous virus genotypes contributed to changes in vaccine effectiveness over time. A mathematical model of mumps transmission confirmed the central role of waning immunity to the vaccine in the re-emergence of mumps cases. Outbreaks from 2006 to the present among young adults, and outbreaks in the late 1980s and early 1990s among adolescents, aligned with peaks in mumps susceptibility of these age groups predicted to be due to loss of vaccine-derived protection. In contrast, evolution of mumps virus strains escaping immune pressure would be expected to cause a higher proportion of cases among children, not adolescents and young adults as observed. Routine use of a third vaccine dose at 18 years of age, or booster dosing throughout adulthood, may be a strategy to prevent mumps re-emergence and should be assessed in clinical trials.

## INTRODUCTION

Over the last decade, mumps outbreaks have thwarted the goal of eliminating indigenous or nonimported mumps virus transmission in the United States by the year 2010 (1, 2). Whereas more than 90% of U.S.-born children experienced mumps infections by 20 years of age in the prevaccine era (3), incidence declined substantially after licensure of a live attenuated vaccine (the Jeryl Lynn vaccine) in 1967, in particular after the 1977 recommendation for its routine use among infants as part of the measles-mumps-rubella (MMR) vaccine (2). Outbreaks among vaccinated middle school- and high school-aged children arose in the late 1980s, followed by sustained reductions in incidence after children were recommended to receive a second MMR dose at 4 to 6 years of age (4). However, an ongoing resurgence in mumps cases began with a series of outbreaks on university campuses in 2006 (2). An older age of infection (ages 18 to 29 years, compared to the prevaccine average of 5 to 9 years) has been a defining feature of these outbreaks (5), similar to recent occurrences in Canada, western Europe, and Asian countries with routine MMR vaccination (6–9).

These circumstances are troubling on two fronts. First, as many as 10% of mumps infections acquired after puberty may cause severe complications including orchitis, meningitis, and deafness, in contrast to a milder clinical course in children that typically involves fever and parotid gland swelling (10). Second, most mumps cases in recent outbreaks have been reported among young adults who received two vaccine doses as recommended (11). This observation has prompted concerns about suboptimal performance of the Jeryl Lynn vaccine currently in use (12).

It is unclear whether recent outbreaks in vaccinated communities are due to the waning of vaccine-derived immunity or to the emergence

of mumps virus strains escaping vaccine-driven immunological pressure. Distinguishing between these possibilities is critical to policy-makers and members of the scientific and medical communities: At issue is whether the re-emergence of mumps can be prevented by modifying vaccine dosing schedules or whether a new vaccine must instead be developed (12).

To this end, we sought to distinguish waning of vaccine-derived protection from long-term changes in vaccine effectiveness against circulating mumps strains using data from six epidemiological studies of mumps vaccine effectiveness performed over past decades in the United States and Europe (table S1). Pooling data from these studies, we tested whether the strength of vaccine-derived immune protection declines with time since receipt of the vaccine—a pattern that would suggest vaccine waning—and whether the degree of protection has changed over recent decades amid shifts in the circulating population of mumps virus lineages. We then measured the potential impact of the waning of vaccine-derived immunity on the susceptibility of the U.S. population to mumps over the decades since vaccine licensure and used mathematical models to assess whether recent mumps virus transmission dynamics are more consistent with hypotheses of waning immunity or vaccine escape. Specifically, we compared expected age-specific infection incidence in stochastic simulations of mumps transmission within two hypothetical vaccinated populations. The first was subject to waning protection based on our estimates of the duration of vaccine-derived immunity; the second experienced durable protection but confronted mumps virus strains against which vaccination provided low degrees of protection. We used our findings to evaluate alternative vaccination policies aiming to enhance protection among adults.

## RESULTS

### Evidence of waning immunity in studies of vaccine effectiveness

Uncertainty about the protective efficacy of the Jeryl Lynn mumps vaccine—ranging from 95% after a single dose in randomized controlled trials (13) to <50% two-dose effectiveness during recent outbreaks

Copyright © 2018  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim  
to original U.S.  
Government Works

<sup>1</sup>Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. <sup>2</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. <sup>3</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

\*Corresponding author. Email: jlewnard@hsph.harvard.edu (J.A.L.); ygrad@hsph.harvard.edu (Y.H.G.)

(14)—has undermined efforts to gauge population immunity. This variation in estimates of effectiveness permitted us to evaluate several hypotheses about the reasons mumps cases have re-emerged among vaccinated persons (2, 12). Fitting a meta-regression model to data from prospective and retrospective cohort studies (table S1), we identified that the time elapsed since receipt of an individual's last vaccine dose accounted for 66.4% of unexplained variation in published vaccine effectiveness estimates (Fig. 1, A to C). Applying our estimate of the vaccine waning rate to a model of exponentially distributed durations of protection, we estimated that immunity persists, on average, 27.4 years [95% confidence interval (CI), 16.7 to 51.1 years] after receipt of any dose. Among 96.4% (95% CI, 94.0 to 97.8%) of individuals expected to mount primary responses to mumps vaccination, we thus expected that 25% may lose protection within 7.9 years (95% CI, 4.7 to 14.7 years), 50% within 19.0 years (95% CI, 11.2 to 35.4 years), and 75% within 38.0 years (95% CI, 22.4 to 70.8 years).

The gradual replacement of predominantly A-genotype mumps virus in the prevaccine era by mixed genotypes after vaccine introduction has also been suspected to contribute to diminished protection. However, we found no evidence for a decline in vaccine effectiveness over the years 1965 to 2006, in particular after controlling for the effect of vaccine waning (Fig. 1D). Whereas we estimated a nonsignificant 1.29 (95% CI, 0.70 to 2.37)-fold increase in the relative risk of infection given vaccination for each log year after 1964 in unadjusted analyses, this trend did not persist (adjusted relative risk, 0.85; 95% CI, 0.56 to 1.30) after controlling for longer time since vaccination among older-age subjects in later studies.

Moreover, we did not identify a difference in the duration of protection after a first dose of vaccine as compared to the duration of protection after a second dose (Fig. 1E). Whereas second doses were originally recommended to bolster immunity in case of failed “take” of the first dose, our findings suggested that the second dose also restores immunity to the degree achieved before waning of the first dose, thus extending protection to older ages. Together, our findings support the central role of waning immune protection as a driver of variation in vaccine performance.

### Changes in population susceptibility to mumps virus after vaccine introduction

To understand the epidemiologic context of mumps resurgence in older age groups, we assessed how waning vaccine-derived immunity and declining rates of natural transmission have affected the susceptibility of the U.S. population over the decades since vaccine introduction. We inferred the degree of immune protection as of 1967, when the vaccine was licensed, by fitting a mathematical model (table S2 and fig. S1) to reproduce epidemiological dynamics in the prevaccine era at steady state (15). We estimated that the basic reproductive number ( $R_0$ ) of mumps in the United States—the number of infections expected to result from an initial index case in a fully susceptible population—was 4.79 before vaccine rollout, in agreement with previous estimates of 3 to 7 for high-income settings in the 20th century (16, 17). Allowing for loss of naturally acquired immunity did not improve model fit (15), consistent with longer-term persistence of high antibody titers after natural infection in comparison to vaccination in children (18).

The ongoing resurgence in mumps among young adults corresponded to cohort-specific changes in susceptibility resulting from vaccine waning and declining transmission over the decades since vaccine rollout (Fig. 2 and fig. S2). We estimated that 52.8% (95% CI, 41.6 to 63.1%) of adults ages 20 to 24 years and 52.6% (95% CI, 42.4 to 61.3%) of adults

ages 25 to 29 years were susceptible to mumps virus infection in 2006 at the outset of the ongoing resurgence, in contrast to 33.8% (95% CI, 30.4 to 37.6%) and 25.2% (95% CI, 22.8 to 27.5%), respectively, as of 1990 and <10% in each age group before vaccine introduction. Susceptibility has also permeated older age groups amid the replacement of cohorts that experienced mumps as children. Whereas most individuals ages 65 years and older had natural immunity as of 2016, we estimated that 29.2% (95% CI, 24.7 to 32.3%) of those ages 40 to 64 years were at risk of infection.


In a further validation of model predictions, the emergence and disappearance of mumps outbreaks among adolescents during the late 1980s and early 1990s corresponded to a transient increase in predicted susceptibility at ages 10 to 19 years (Fig. 2). We estimated that susceptibility at ages 10 to 14 years peaked in 1991, when 45.8% (95% CI, 39.3 to 52.4%) of children in this age group were at risk for infection, together with 43.0% (95% CI, 37.3 to 49.0%) of adolescents ages 15 to 19 years. These estimates reflect 2.85 (95% CI, 2.65 to 3.30)-fold and 3.96 (95% CI, 3.43 to 4.52)-fold increases in age-specific susceptibility, respectively, compared to the prevaccine era. Whereas breakthrough outbreaks beginning in the 1980s were hypothesized at that time to reflect inadequate responses of children to their first vaccine dose (19), our findings instead suggest that vaccine waning and declining natural exposure explain why adolescents were the population at highest risk for infection at that time.

We estimated that, as of 2016, the prevalence of susceptibility among children ages 10 to 14 years declined to 34.8% (95% CI, 24.3 to 45.7%) because of the recommendation in 1989 for children to receive a second dose at ages 4 to 6 years (4). Whereas most adolescents experiencing cases during the initial resurgence had received one dose of vaccine in keeping with the recommendations at that time (20, 21), recent outbreaks have predominantly included individuals eligible to receive two doses (fig. S3). Thus, the increasing age of infection in the United States more likely tracks with cases due to waning immunity after receipt of the second dose rather than a continuation of cases within a single, underimmunized cohort. These findings hold in sensitivity analyses assuming 1 and 2% annual declines in reporting effort (corresponding to 39 and 63% overall reductions in disease reporting by 2017) over the decades since vaccine introduction (figs. S4 and S5).


### Predicted transmission dynamics under vaccine waning and viral escape

Our analyses have suggested that reduced vaccine effectiveness relates primarily to waning protection rather than the emergence of mumps virus genotypes escaping vaccine-driven immunity. However, our ability to compare these hypotheses using data from previous studies is limited by a lack of data about genotype-specific protection. To better understand whether recent outbreaks are more consistent with vaccine waning or viral escape, we used a stochastic transmission model to compare expected epidemiologic dynamics under these scenarios in the year 2006, when the ongoing resurgence began. Using the approach taken above to update population immunity and transmission parameters in the absence of waning vaccine immunity (figs. S6 and S7), we simulated the spread of mumps virus strains against which the vaccine provided partial protection in a population of 1 million.

Under age-structured social mixing patterns that formerly caused mumps cases to center among school-aged children, waning of vaccine protection is a necessary mechanism to account for shifts in the age distribution of cases toward adolescence and young adulthood. We found that strains capable of vaccine escape would be expected to cause higher-than-observed incidence among younger children (Fig. 3, A



**Fig. 1. Synthesis of prospective and retrospective cohort studies estimating the relative risk of clinical mumps in vaccinated and unvaccinated individuals.** We illustrate the results of our meta-analysis of studies of mumps vaccine effectiveness, from which we estimated rates of vaccine waning. **(A)** Shown here is how estimates of vaccine effectiveness (defined as one minus the relative risk (RR) of experiencing mumps for a vaccinated individual, relative to an unvaccinated individual) differ across the six studies analyzed here. Time since last dose accounts for 66.4% of residual variation in estimates after accounting for random sources of between-study heterogeneity. Points representing study-level estimates are scaled in size to reflect differences in sample size. Lines signify 95% confidence intervals (CIs); arrows indicate where values rounded to the nearest hundredth equal zero. **(B)** At 6 months after vaccine receipt (the earliest time point assessed in primary studies), we estimate that 96.4% (94.0 to 97.8%) of recipients are protected; we apply this as our estimate of the probability of vaccine take. **(C)** A parsimonious model of exponentially distributed durations of protection predicts loss of protection after, on average,  $\frac{1}{\omega_v} = 27.4$  years (95% CI, 16.7 to 51.1), as indicated by the yellow-plotted area. The blue-plotted area illustrates the distribution of times to loss of protection for vaccinated individuals, generated by pooling exponential distributions parameterized using estimates of  $\omega_v$ . **(D)** Contrary to the hypothesis of reduced effectiveness against diverse mumps genotypes currently in circulation, we did not identify evidence of a decline in vaccine effectiveness over time, whereas evidence of waning vaccine-derived immunity persisted in a model adjusting for calendar year. Unadjusted estimates of the relative risk of clinical mumps given vaccination—and estimates adjusted for time since vaccination, years since 1964, and doses received—are calculated via meta-regression using incidence data from the original studies (13, 46–50). **(E)** Using this meta-regression framework, we identified no difference (posterior two-sided  $P > 0.1$ ) in the waning rate (as defined by the inverse of the association between time since vaccination and relative risk of mumps given vaccination; see Materials and Methods) after receipt of a first or second dose (95% CI, 33% decrease to 72% increase in the relative risk of mumps given vaccination per log year since vaccination; posterior two-sided  $P > 0.1$ ).




**Fig. 2. Mumps incidence and estimates of population susceptibility over time.** Here, we illustrate changes in the proportion of the population, by age, predicted to be susceptible to mumps on the basis of the estimated waning rate of vaccine-derived immune protection and the incidence of mumps infection in the population. **(A)** Overall rates of reported cases declined after vaccine licensure in 1967, punctuated by outbreaks primarily among adolescents from 1984 to 1992 and recent outbreaks (2006 onward) centered among young adults. These outbreaks have corresponded with **(B)** peaks in the model-inferred proportion of individuals susceptible to mumps infection at 10 to 19 and 20 to 29 years of age, respectively, and **(C)** reductions in the proportion of infections that cause symptoms and are reported because of vaccine protection against symptoms. **(D)** Changes in the proportion of individuals susceptible to infection across different ages are plotted against rates of reported cases.

to E). In contrast to the median age of mumps cases of 22 years reported in 2006, the predicted median age of cases approached 14.2 years (95% CI, 8.3 to 21.7 years) as strain-specific vaccine effectiveness declined to 0%. Although strains with lower ability to escape immune pressure may not concentrate to such an extent among children, we expected such strains to cause low incidence in a population unaffected by waning immunity (Fig. 3F). Model-predicted overall rates of mumps incidence exceeded reported rates at lower degrees of cross-protection. As compared to predictions under scenarios of viral escape, model-predicted dynamics under vaccine waning provided a closer match to reported overall and

age-specific incidence, with an expected median age of 22.3 years (95% CI, 17.7 to 26.3 years) among cases.

### Potential impact of booster vaccination

If vaccine-derived immunity wanes or confers shorter-lasting protection against genotypes currently in circulation as compared to those circulating in 1967, then administering additional vaccine doses may help control transmission by extending immune protection to older ages. On the basis of analyses of the effective reproductive number ( $R_E$ ), or the number of new infectious cases emerging from a single infectious case



**Fig. 3. Anticipated transmission dynamics under scenarios of vaccine escape and vaccine waning.** Here, we use a stochastic simulation model to predict the epidemiology of mumps outbreaks under the scenario of mumps virus escaping vaccine-induced immune pressure and the scenario of waning vaccine-derived immunity. (A) A stochastic model of an emerging vaccine-escape strain of mumps virus in a vaccinated population predicts excess incidence in young age groups, in keeping with their higher historical burden of mumps. (B) In contrast, the fit of a model incorporating waning vaccine-derived immunity matches the observed age distribution. (C) Higher overall incidence rates and (D) a younger age distribution of cases are predicted when immune responses to the vaccine offer minimal cross-protection against the circulating strain, as compared to the fit of the model with waning vaccine immunity. (E) Whereas the model with a viral-escape (VE) strain can reproduce the age distribution of cases at low degrees of immunological mismatch, (F) lower-than-reported incidence is expected under this scenario, again in contrast to the fit of a model with waning vaccine immunity. Lines in (E) and (F) signify 95% CIs.


under prevailing levels of immunity, we found that protection afforded by two vaccine doses alone is unlikely to support elimination of endemic mumps virus transmission from the United States in the long term. If  $R_E$  stays below 1.0, then epidemics are unlikely to be sustained in the long term; because birth cohorts exposed to high rates of transmission in the 20th century are replaced by individuals whose protection comes only through vaccination, we expect  $R_E$  to approach 1.11 (95% CI, 1.04 to 1.13; Fig. 4). Although administering a third vaccine dose by 18 years of age would not necessarily confer life-long protection based on our estimate of the time to loss of immunity, we nonetheless predict that this intervention could extend protection through young adulthood, thereby protecting age groups at risk in recent outbreaks. Low (56%) uptake of a third dose matching adult compliance with recommended tetanus-diphtheria toxoid booster doses would be expected to sustain  $R_E$  around 0.88 (95% CI, 0.83 to 0.91), based on transmission dynamics in the United States as of 2016. Under a more optimistic scenario of 88% third-dose coverage—where third-dose uptake equates second-dose uptake among already-immunized individuals—we expect  $R_E$  to approach 0.77 (95% CI, 0.72 to 0.79) as cohorts previously exposed to high transmission rates age out of the population.

Whereas we estimated that most older adults are currently immune to mumps virus because of previous infection, our modeling suggested that neither a two-dose nor a three-dose vaccination program would be expected to protect more than 50% of adults beyond the age of 40 years in the long term. This concern may motivate the use of routine booster doses in adulthood (Fig. 4). On the basis of our model, we expect that administering additional doses every 10 or 20 years would lead to sus-

tained protection in, at minimum, 68.0% (95% CI, 58.5 to 77.6%) and 55.2% (95% CI, 44.1 to 68.4%) of the population, respectively, under a scenario of 88% vaccine coverage; at the lower (56%) coverage level, we estimated protection among, at minimum, 59.0% (95% CI, 48.2 to 71.2%) and 45.5% (95% CI, 34.3 to 60.5%) of adults with dosing every 10 or 20 years, respectively. Maintaining high prevalence of immunity in the population through repeated dosing may also help to contain emergence of new mumps virus strains (Fig. 4E). To sustain  $R_E \geq 1$  under three-dose schedules, we estimated that an emerging strain would require, at minimum, 8.5% (95% CI, 7.6 to 9.8%) to 15.7% (95% CI, 11.9 to 20.3%) probability of causing infection in exposed persons otherwise protected by vaccination. Adding booster doses every 10 years increased this threshold probability to between 16.6% (95% CI, 12.5 to 20.8%) and 22.9% (95% CI, 16.4 to 29.7%) at varying degrees of vaccine coverage.

## DISCUSSION

Resurgent outbreaks centered among young adults have brought renewed attention to mumps after decades of progress toward its elimination from the United States (2, 12). Understanding why cases have re-emerged is essential for determining how to contain the disease through vaccination. Our analyses show that vaccine-derived immune protection wanes over time. We estimate the rate of waning and demonstrate that this waning immunity accounts for susceptibility in the age groups experiencing outbreaks over the decades since vaccine introduction in the United States. In contrast, changes in the circulating genotypes of mumps virus over this same period have not been



**Fig. 4. Age-specific immunity and transmission dynamics under two- and three-dose vaccine schedules.** Waning vaccine-derived protection in the population raises the question of how additional vaccine doses would affect mumps transmission. To address this question, we evaluated several scenarios. **(A)** Cohorts over 40 years of age as of 2016 were exposed to endemic transmission before and shortly after vaccine rollout and likely retain life-long protection. However, a population protected only by two-dose vaccination would be expected to experience high prevalence of susceptibility over 20 years of age. **(B and C)** Our modeling suggests that the duration of protection can be extended through young adulthood by adding a third dose around 18 years of age, whereas routine booster doses every 10 or 20 years would be expected to sustain longer-term protection. Lines and shaded areas delineate median estimates and 95% CIs, respectively. **(D)** Under transmission dynamics estimated as of 2016, protection in young adult age groups achieved through the use of a third vaccine dose is expected to reduce the effective reproductive number ( $R_E$ ) below 1. We, however, predict  $R_E$  to approach 1.10 under the two-dose schedule as cohorts that experienced high rates of mumps infection age out of the population; larger reductions in  $R_E$  are sustained at higher coverage and with more frequent dosing. Colors are the same as in (A) to (C).  $R_0$ , basic reproductive number. **(E)** In turn, these extensions of protection provide a stronger barrier against emergence of strains escaping vaccine immunity. A new strain with 8.5% (95% CI, 7.6 to 9.8%) probability of evading vaccine-induced immunity and infecting a vaccine-protected individual would be expected to succeed under a three-dose schedule with low coverage. We, however, estimate that a new strain would require 22.9% (95% CI, 16.4 to 29.7%) probability of infecting such an individual to emerge in a population with 88% uptake of the third dose and 10-year boosters. Lines denote 95% CIs, and shaded areas represent distributions around  $R_E$  estimates.

associated with reductions in vaccine effectiveness; moreover, our modeling suggests that mumps virus strains escaping vaccine protection would be expected to cause disproportionate incidence among younger children, which has not been observed in most recent outbreaks. Guided by these outcomes, our model shows that routine use of a third vaccine dose around 18 years of age, with or without regular dosing in adulthood, could help maintain immune protection in the population.

Distinguishing between the contributions of vaccine waning and the emergence of vaccine-escape virus strains to mumps resurgence helps inform whether new vaccines are needed to control transmission (22, 23). Our findings that vaccine effectiveness has not declined amid the replacement of genotype A mumps viruses (from which the Jeryl Lynn vaccine strain was derived), and that the age distribution of recent cases is inconsistent with expectations under vaccine escape, are in agreement with several lines of evidence that mumps vaccination protects broadly against heterologous strains (24). Neutralizing antibody responses to the Jeryl Lynn strain are effective in vitro against wild-type mumps virus strains responsible for recent outbreaks among vaccinated individuals (25, 26), and genetic distinctions have not been identified between strains isolated from vaccinated and unvaccinated

mumps patients (27). High efficacy and effectiveness estimates for both the Jeryl Lynn (genotype A–derived) and Urabe (genotype B–derived) vaccines against clinical illness caused by heterologous mumps genotypes further substantiate the notion of cross-neutralizing or monotypic immune responses (12).

Although the efficacy of a third dose has not been assessed in clinical trials, several observations suggest effectiveness of extended vaccine schedules. Although congregated U.S. military populations resemble high-risk groups based on their age distribution and close-contact environments, no outbreaks have been reported in the military since a policy of administering an MMR dose to incoming recruits, regardless of vaccination history, was adopted in 1991 (28). In addition, receiving a third dose was associated with protection in a recent observational study after a third-dose campaign undertaken in response to a university campus outbreak (29), building on limited evidence from previous studies where third doses were only administered at the tail end of outbreaks (30–33). Trials demonstrating the clinical effectiveness of adult vaccine doses remain ideal to guide policy around the benefits of routine or reactive use of third doses and may improve our understanding of immunological correlates of protection (34–36). Such trials—or further observational studies—will also play an important role in establishing

the duration of protection after third or additional doses in adulthood. Modifying MMR vaccines to improve the magnitude or duration of immune responses against mumps virus may also improve protection. Notably, the mumps component of the vaccine induces lower-avidity antibody responses, and weaker specific memory B cell proliferation, than the measles and rubella components (37, 38).

Several limitations of the analysis should be considered. Our use of aggregated rather than individual-level data from vaccine effectiveness studies contributed to an imprecise estimate of the time to loss of immunity, in turn limiting the precision of our estimates of population susceptibility. Individual-level data from postlicensure vaccine studies could support better inferences about the magnitude and duration of vaccine protection, thus aiding policy decisions. Identifying immunological correlates of protection from such data sets would also aid evaluations of alternative vaccination schedules and measurements of population immunity. Second, we lack data on genotype-specific incidence that could help us infer differential protection of the Jeryl Lynn vaccine against circulating strains. Epidemiological studies of outbreaks caused by distinct virus lineages, and in populations exposed to different circulating mumps viruses, can better characterize genotype specificity in the strength or duration of vaccine protection. Last, our analysis addresses mumps epidemiology in the United States, where prevalence of immunity within particular birth cohorts may differ in relation to settings that introduced routine mumps vaccination later or use different vaccine schedules. The burden of cases and prevalence of immunity across ages or birth cohorts should be considered as a basis to guide vaccination policy within specific countries.

Analyzing nationally aggregated incidence data sets also limited our ability to investigate how geographic or socioeconomic differences in vaccine uptake and contact rates contribute to the dynamics of focal outbreaks, as might occur in close-contact settings such as university dormitories (39, 40). However, our inferences about vaccine waning and the changing age distribution of mumps cases offer insight into why mumps resurgence has been possible throughout geographically and socioeconomically distinct communities. In this regard, the widespread re-emergence of mumps in vaccine-compliant communities stands in stark contrast to the focal re-emergence of measles in communities with low vaccine coverage (11).

Changes in the epidemiology of mumps have implications for disease surveillance. Diminished clinical awareness of mumps, expectations that it appears in pediatric rather than adult populations, and protection against symptoms in vaccinated individuals (41) may limit routine detection of cases and thus bias disease reporting. Serological surveys have provided evidence of higher-than-reported rates of mumps virus infection in the United States before 2006 (28, 42). The tendency to identify outbreak-associated cases through contact tracing may also favor detection of cases in university campuses and other closely connected populations, underscoring the importance of epidemiological surveillance to identify infections occurring in the community.

The ongoing resurgence in mumps among young adults has undermined previous enthusiasm about near-term elimination of this disease from the United States (1). Our analysis suggests that vaccinated individuals lose protection against infection on average 27 years after receipt of their last dose and that this rate of vaccine waning explains susceptibility in adolescent and young adult cohorts at the time of post-licensure outbreaks in these age groups. Re-emergence of mumps among older, previously vaccinated individuals whose immunity has waned parallels recent experience with varicella outbreaks affecting immunized communities as a result of waning vaccine-derived protection (43). As

demonstrated in mumps epidemiology, immunity in previously infected cohorts may buffer transmission and delay breakthrough epidemics from occurring until decades after vaccine introduction. We expect population susceptibility to mumps to continue increasing as transient vaccine-derived immunity supersedes previous infection as the main determinant of mumps susceptibility in the U.S. population. These observations indicate the need for either innovative clinical trial designs to measure the benefit of extending vaccine dosing schedules or new vaccines to address the problem of waning vaccine-induced protection (44).

## MATERIALS AND METHODS

### Study design

Our study is composed of four parts. First, we conducted a meta-analysis of six studies on mumps vaccine effectiveness in the United States and Europe to assess hypotheses of waning protection and diminished effectiveness against currently circulating strains. We then applied estimates of the waning rate from this analysis to infer changes over time in the susceptibility of the U.S. population, accounting for vaccine uptake and incidence of natural infection. We integrated a system of differential equations forward from initial conditions, defined from the prevaccination endemic equilibrium (as inferred over the years 1960 to 1964), by back-calculating transmission rates from reported mumps incidence. We next modeled expected transmission dynamics under scenarios of vaccine waning and viral escape and estimated long-term impacts of adult vaccination schedules on population susceptibility. Full technical details pertaining to our analyses are presented in Supplementary Materials and Methods (a brief summary is provided here).

### Meta-analysis of vaccine effectiveness studies

We performed a systematic review of prospective and retrospective cohort studies calculating effectiveness of the Jeryl Lynn strain mumps vaccine via a PubMed search and citation tracking. Details of the studies used to infer vaccine effectiveness are listed in table S1. We used an inverse variance-weighted meta-regression model, accounting for study-level heterogeneity, to measure unadjusted and multivariate-adjusted associations of the following variables with study-level estimates of the relative risk of infection associated with vaccination: (i) time since receipt of the last vaccine dose, indicating waning vaccine immunity; (ii) time from 1964 (when the Jeryl Lynn vaccine was developed) to the year of mumps exposure, indicating long-term changes in vaccine effectiveness associated with changes in circulating genotypes; and (iii) vaccine doses received, with an interaction term for time since the last dose to test for differential waning of first and second doses.

Regression model summary statistics indicated the proportion of variance explained by these covariates. We used our estimate of the association between instantaneous risk of infection and time since vaccination to fit an exponential distribution to the duration of vaccine-derived immune protection and used this fitted distribution as the basis for further modeling.

### Modeling population immunity and mumps virus transmission

We used a system of ordinary differential equations to describe changes in the population of susceptible and protected persons, partitioned into those who had and had not received mumps vaccines. Updating the model to address the contributions of vaccination and vaccine waning

to population immunity, we back-calculated changes in natural immunity in the population based on the relation

$$\Lambda(i, t) \propto \lambda(i, t) [\pi_U S(i, t) + \pi_V F(i, t)]$$

between reported incidence rates ( $\Lambda$ ) in age group  $i$  and year  $t$  and the force of infection to which individuals were exposed ( $\lambda$ ), the populations of susceptible unvaccinated ( $S$ ) and vaccinated ( $F$ ) persons, and the probabilities ( $\pi_U$  and  $\pi_V$ , respectively) for these individuals to experience symptoms if infected. As described in Supplementary Materials and Methods, this approach allowed us to account for changes over time in transmission patterns leading to time-varying estimates of the basic reproductive number. Susceptible vaccinated persons ( $F$ ) comprised those failing to mount an immune response immediately after vaccination (primary vaccine failure) and those whose initial protection had waned (secondary vaccine failure). Model parameter values and their sources are listed in table S2. Age-specific incidence reports were collated from nationwide surveillance (45). Our model accounted for age-structured mixing among individuals partitioned across 10 age classes (0 to 11 months, 1 to 4 years, 5 to 9 years, 10 to 14 years, 15 to 19 years, 20 to 24 years, 25 to 29 years, 30 to 39 years, 40 to 64 years, and  $\geq 65$  years). Members of the  $i$ th age class encountered the force of infection

$$\lambda(i) \propto \sum_{j=1}^{10} C_{(S)}(i, j) \frac{I(j)}{N(j)}$$

cumulatively through interactions with infectious individuals ( $I$ ) distributed across all  $j$  age classes; the matrix  $C_{(S)}$  conveyed age-specific mixing patterns. We inferred starting-time age-specific prevalence of immunity in the U.S. population (as of 1967) by fitting a mathematical model of mumps transmission to recapitulate age-specific incidence in the prevaccine era at steady state. To compare predicted incidence during an introduced outbreak against observations from the year 2006, we implemented stochastic realizations of extended versions of the model under scenarios where we assumed waning of immunity or circulation of strains with differential risk of infecting persons protected by vaccination. We assessed which scenario was more consistent with epidemiological observations on the basis of model-predicted age-specific and overall incidence rates, as well as the predicted median age of infection.

### Assessing extended-dose strategies

We compared the long-term performance of different vaccination schedules including the addition of a third dose by 18 years of age and the use of routine boosters at 10- or 20-year intervals through adulthood. We calculated the prevalence of age-specific immune protection achieved under these strategies and resulting values of the effective reproductive number ( $R_E$ ), describing the number of cases an infectious individual would be expected to cause under prevailing conditions. We also calculated the minimum probability of immune escape a novel mumps virus strain would need to invade a population protected under these different strategies, defined as the minimum probability of infecting a vaccinated, protected individual upon exposure such that  $R_E \geq 1$ .

### SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/10/433/eaao5945/DC1

Materials and Methods

Fig. S1. Fitted endemic transmission dynamics before vaccine rollout.

Fig. S2. Reductions in mumps notifications correspond with increases in vaccine coverage and a declining basic reproductive number.

Fig. S3. Birth cohorts accounting for reported cases over time.

Fig. S4. Changes in estimates of the susceptible population under scenarios of declining reporting.

Fig. S5. Changes in estimates of  $R_0$  over time under scenarios of declining reporting.

Fig. S6. Aggregated age-specific notification rates.

Fig. S7. Estimates of population susceptibility and  $R_0(t)$  under an assumption of time-invariant protection.

Table S1. Studies included in meta-analysis assessing vaccine waning.

Table S2. Model parameter definitions and values.

References (51–81)

### REFERENCES AND NOTES

1. National Center for Health Statistics, Healthy People 2010: Final Review (U.S. Centers for Disease Control and Prevention, 2012); www.cdc.gov/nchs/data/hpdata2010/hp2010\_final\_review.pdf.
2. G. H. Dayan, M. P. Quinlisk, A. A. Parker, A. E. Barskey, M. L. Harris, J. M. H. Schwartz, K. Hunt, C. G. Finley, D. P. Leschinsky, A. L. O'Keefe, J. Clayton, L. K. Kightlinger, E. G. Dietle, J. Berg, C. L. Kenyon, S. T. Goldstein, S. K. Stokley, S. B. Redd, P. A. Rota, J. Rota, D. Bi, S. W. Roush, C. B. Bridges, T. A. Santibanez, U. Parashar, W. J. Bellini, J. F. Seward, Recent resurgence of mumps in the United States. *N. Engl. J. Med.* **358**, 1580–1589 (2008).
3. M. B. Meyer, An epidemiologic study of mumps; its spread in schools and families. *Am. J. Hyg.* **75**, 259–281 (1962).
4. Centers for Disease Control and Prevention (CDC), Measles prevention: Recommendations of the immunization practices advisory committee (ACIP). *Morb. Mortal. Wkly. Rep.* **38**, 1–18 (1989).
5. H. Q. McLean, A. P. Fiebelkorn, J. L. Temte, G. S. Wallace; Centers for Disease Control and Prevention, Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morb. Mortal. Wkly. Rep.* **62**, 1–34 (2013).
6. E. Savage, Mumps outbreaks across England and Wales in 2004: Observational study. *BMJ* **330**, 1119–1120 (2005).
7. J. Sane, S. Gouma, M. Koopmans, H. de Melker, C. Swaan, R. van Binnendijk, S. Hahné, Epidemic of mumps among vaccinated persons, the Netherlands, 2009–2012. *Emerg. Infect. Dis.* **20**, 643–648 (2014).
8. G. St-Martin, L. K. Knudsen, F. N. Engsig, I. Panum, P. H. S. Andersen, J. Rønn, J. Fonager, T. K. Fischer, Mumps resurgence in Denmark. *J. Clin. Virol.* **61**, 435–438 (2014).
9. H. Peltola, P. S. Kulkarni, S. V. Kapre, M. Paunio, S. S. Jadhav, R. M. Dhere, Mumps outbreaks in Canada and the United States: Time for new thinking on mumps vaccines. *Clin. Infect. Dis.* **45**, 459–466 (2007).
10. R. M. Anderson, J. A. Crombie, B. T. Grenfell, The epidemiology of mumps in the UK: A preliminary study of virus transmission, herd immunity and the potential impact of immunization. *Epidemiol. Infect.* **99**, 65–84 (1987).
11. V. K. Phadke, R. A. Bednarczyk, D. A. Salmon, S. B. Omer, Association between vaccine refusal and vaccine-preventable diseases in the United States: A review of measles and pertussis. *JAMA* **315**, 1149–1158 (2016).
12. G. H. Dayan, S. Rubin, S. Plotkin, Mumps outbreaks in vaccinated populations: Are available mumps vaccines effective enough to prevent outbreaks? *Clin. Infect. Dis.* **47**, 1458–1467 (2008).
13. M. R. Hilleman, R. E. Weibel, E. B. Buynak, J. Stokes Jr., J. E. Whitman Jr., Live, attenuated mumps-virus vaccine—Protective efficacy as measured in a field evaluation. *N. Engl. J. Med.* **276**, 252–258 (1967).
14. R. Harling, J. M. White, M. E. Ramsay, K. F. Macsween, C. van den Bosch, The effectiveness of the mumps component of the MMR vaccine: A case control study. *Vaccine* **23**, 4070–4074 (2005).
15. Full materials and methods and results of sensitivity analyses are presented in the Supplementary Materials.
16. P. E. M. Fine, Herd immunity: History, theory, practice. *Epidemiol. Rev.* **15**, 265–302 (1993).
17. J. Wallinga, P. Teunis, M. Kretzschmar, Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. *Am. J. Epidemiol.* **164**, 936–944 (2006).
18. B. Christenson, M. Böttiger, Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. *Biologicals* **18**, 213–219 (1990).
19. S. L. Cochi, S. R. Preblud, W. A. Orenstein, Perspectives on the relative resurgence of mumps in the United States. *Am. J. Dis. Child.* **142**, 499–507 (1988).
20. J. E. Cheek, R. Baron, H. Atlas, D. L. Wilson, R. D. Crider Jr., Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure. *Arch. Pediatr. Adolesc. Med.* **149**, 774–778 (1995).
21. P. A. Briss, L. J. Fehrs, R. A. Parker, P. F. Wright, E. C. Sannella, R. H. Hutcheson, W. Schaffner, Sustained transmission of mumps in a highly vaccinated population: Assessment of

- primary vaccine failure and waning vaccine-induced immunity. *J. Infect. Dis.* **169**, 77–82 (1994).
22. S. A. Plotkin, Mumps vaccines: Do we need a new one? *Pediatr. Infect. Dis. J.* **32**, 381–382 (2013).
  23. S. A. Rubin, J. Beeler, Mumps vaccines: Do we need a new one? *Pediatr. Infect. Dis. J.* **32**, 1156–1157 (2013).
  24. S. A. Rubin, M. A. Link, C. J. Sauder, C. Zhang, L. Ngo, B. K. Rima, W. P. Duprex, Recent mumps outbreaks in vaccinated populations: No evidence of immune escape. *J. Virol.* **86**, 615–620 (2012).
  25. S. A. Rubin, L. Qi, S. A. Audet, B. Sullivan, K. M. Carbone, W. J. Bellini, P. A. Rota, L. Sirota, J. Beeler, Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. *J. Infect. Dis.* **198**, 508–515 (2008).
  26. S. Rubin, J. Mauldin, K. Chumakov, J. Vanderzanden, R. Iskow, K. Carbone, Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. *Vaccine* **24**, 2662–2668 (2006).
  27. S. Utz, J.-L. Richard, S. Capaul, H. C. Matter, M. G. Hrisoho, K. Mühlemann, Phylogenetic analysis of clinical mumps virus isolates from vaccinated and non-vaccinated patients with mumps during an outbreak, Switzerland 1998–2000. *J. Med. Virol.* **73**, 91–96 (2004).
  28. A. A. Eick, Z. Hu, Z. Wang, R. L. Nevin, Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000–2004. *Vaccine* **26**, 494–501 (2008).
  29. C. V. Cardemil, R. M. Dahl, L. James, K. Wannemuehler, H. E. Gary, M. Shah, M. Marin, J. Riley, D. R. Feiken, M. Patel, P. Quinlisk, Effectiveness of a third dose of MMR vaccine for mumps outbreak control. *N. Engl. J. Med.* **377**, 947–956 (2017).
  30. I. U. Ogbuanu, P. K. Kutty, J. M. Hudson, D. Blog, G. R. Abedi, S. Goodell, J. Lawler, H. Q. McLean, L. Pollock, E. Rausch-Phung, C. Schulte, B. Valure, G. L. Armstrong, K. Gallagher, Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. *Pediatrics* **130**, e1567–e1574 (2012).
  31. J. P. Albertson, W. J. Clegg, H. D. Reid, B. S. Arbise, J. Pryde, A. Vaid, R. Thompson-Brown, F. Echols, Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine—Illinois, 2015–2016. *Morb. Mortal. Wkly. Rep.* **65**, 731–734 (2016).
  32. A. P. Fiebelkorn, J. Lawler, A. T. Curns, C. Brandeburg, G. S. Wallace, Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA. *Emerg. Infect. Dis.* **19**, 1411–1417 (2013).
  33. G. E. Nelson, A. Aguon, E. Valencia, R. Oliva, M. L. Guerrero, R. Reyes, A. Lizama, D. Diras, A. Mathew, E. J. Camacho, M.-N. Monforte, T.-H. Chen, A. Mahamud, P. K. Kutty, C. Hickman, W. J. Bellini, J. F. Seward, K. Gallagher, A. P. Fiebelkorn, Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control—Guam 2009 to 2010. *Pediatr. Infect. Dis. J.* **32**, 374–380 (2013).
  34. A. P. Fiebelkorn, L. A. Coleman, E. A. Belongia, S. K. Freeman, D. York, D. Bi, C. Zhang, L. Ngo, S. Rubin, Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. *Open Forum Infect. Dis.* **1**, ofu094 (2014).
  35. A. A. Date, M. H. Kyaw, A. M. Rue, J. Klahn, L. Obrecht, T. Krohn, J. Rowland, S. Rubin, T. J. Safranek, W. J. Bellini, G. H. Dayan, Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. *J. Infect. Dis.* **197**, 1662–1668 (2008).
  36. M. M. Cortese, A. E. Barskey, G. E. Tegtmeyer, C. Zhang, L. Ngo, M. H. Kyaw, A. L. Baughman, J. E. Menitove, C. J. Hickman, W. J. Bellini, G. H. Dayan, G. R. Hansen, S. Rubin, Mumps antibody levels among students before a mumps outbreak: In search of a correlate of immunity. *J. Infect. Dis.* **204**, 1413–1422 (2011).
  37. X.-X. Gu, S. A. Plotkin, K. M. Edwards, A. Sette, K. H. G. Mills, O. Levy, A. J. Sant, A. Mo, W. Alexander, K. T. Lu, C. E. Taylor, Waning immunity and microbial vaccines—Workshop of the National Institute of Allergy and Infectious Diseases. *Clin. Vaccine Immunol.* **24**, e00034–e17 (2017).
  38. M. Kontio, S. Jokinen, M. Paunio, H. Peltola, I. Davidkin, Waning antibody levels and avidity: Implications for MMR vaccine-induced protection. *J. Infect. Dis.* **206**, 1542–1548 (2012).
  39. M. M. Cortese, H. T. Jordan, A. T. Curns, P. A. Quinlan, K. A. Ens, P. M. Denning, G. H. Dayan, Mumps vaccine performance among university students during a mumps outbreak. *Clin. Infect. Dis.* **46**, 1172–1180 (2008).
  40. J. A. Wright, C. Polack, Understanding variation in measles-mumps-rubella immunization coverage—A population-based study. *Eur. J. Public Health* **16**, 137–142 (2006).
  41. S. Dittrich, S. Hahné, A. van Lier, R. Kohl, H. Boot, M. Koopmans, R. van Binnendijk, Assessment of serological evidence for mumps virus infection in vaccinated children. *Vaccine* **29**, 9271–9275 (2011).
  42. I. J. Amanna, N. E. Carlson, M. K. Slifka, Duration of humoral immunity to common viral and vaccine antigens. *N. Engl. J. Med.* **357**, 1903–1915 (2007).
  43. S. S. Chaves, P. Gargiullo, J. X. Zhang, R. Civen, D. Guris, L. Mascola, J. F. Seward, Loss of vaccine-induced immunity to varicella over time. *N. Engl. J. Med.* **356**, 1121–1129 (2007).
  44. Ebola ça Suffit Ring Vaccination Trial Consortium, The ring vaccination trial: A novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. *BMJ* **351**, h3740 (2015).
  45. D. A. Adams, K. R. Thomas, R. A. Jajosky, L. Foster, P. Sharp, D. H. Onweh, A. W. Schley, W. J. Anderson; Nationally Notifiable Infectious Conditions Group, Summary of notifiable infectious diseases and conditions: United States, 2014. *Morb. Mortal. Wkly. Rep.* **63**, 1–152 (2016).
  46. C. Cohen, J. M. White, E. J. Savage, J. R. Glynn, Y. Choi, N. Andrews, D. Brown, M. E. Ramsay, Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. *Emerg. Infect. Dis.* **13**, 12–17 (2007).
  47. C. Vandermeulen, M. Roelants, M. Vermoere, K. Roseeuw, P. Goubau, K. Hoppenbrouwers, Outbreak of mumps in a vaccinated child population: A question of vaccine failure? *Vaccine* **22**, 2713–2716 (2004).
  48. R. Tizes, S. van Zetta, J. Beaver, A. Krawczyk, A. Hinman, Mumps in an elementary school: New York. *Morb. Mortal. Wkly. Rep.* **22**, 185–186 (1973).
  49. M. Schlegel, J. J. Osterwalder, R. L. Galeazzi, P. L. Vernazza, Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: Cohort study. *BMJ* **319**, 352 (1999).
  50. M. Marin, P. Quinlisk, T. Shimabukuro, C. Sawhney, C. Brown, C. W. LeBaron, Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students—Iowa, 2006. *Vaccine* **26**, 3601–3607 (2008).
  51. C. P. Farrington, The measurement and interpretation of age-specific vaccine efficacy. *Int. J. Epidemiol.* **21**, 1014–1020 (1992).
  52. J. K. Schaffzin, L. Pollock, C. Schulte, K. Henry, G. Dayan, D. Blog, P. Smith, Effectiveness of previous mumps vaccination during a summer camp outbreak. *Pediatrics* **120**, e862–e868 (2007).
  53. P. K. Kutty, H. Q. McLean, J. Lawler, C. Schulte, J. M. Hudson, D. Blog, G. Wallace, Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009–2010. *Pediatr. Infect. Dis. J.* **33**, 121–125 (2014).
  54. C. P. Farrington, Estimation of vaccine effectiveness using the screening method. *Int. J. Epidemiol.* **22**, 742–746 (1993).
  55. A. M. Galazka, S. E. Robertson, A. Kraigher, Mumps and mumps vaccine: A global review. *Bull. World Health Organ.* **77**, 3–14 (1999).
  56. D. Adams, K. Fullerton, R. Jajosky, P. Sharp, D. Onweh, A. Schley, W. Anderson, A. Faulkner, K. Kugeler, Summary of notifiable infectious diseases and conditions – United States, 2013. *Morb. Mortal. Wkly. Rep.* **62**, 1–122 (2015).
  57. I. Mossong, N. Hens, M. Jit, P. Beutels, K. Auranen, R. Mikolajczyk, M. Massari, S. Salmaso, G. S. Tomba, J. Wallinga, J. Heijne, M. Sadkowska-Todys, M. Rosinska, W. J. Edmunds, Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLOS Med.* **5**, e74 (2008).
  58. J. J. Witte, A. W. Karchmer, Surveillance of mumps in the United States as background for use of vaccine. *Public Health Rep.* **83**, 95–100 (1968).
  59. L. P. Levitt, D. H. Mahoney Jr., H. L. Casey, J. O. Bond, Mumps in a general population. A sero-epidemiologic study. *Am. J. Dis. Child.* **120**, 134–138 (1970).
  60. M. Wharton, S. L. Cochi, R. H. Hutcheson, W. Schaffner, Mumps transmission in hospitals. *Arch. Intern. Med.* **150**, 47–49 (1990).
  61. R. N. Philip, K. R. Reinhard, D. B. Lackman, Observations on a mumps epidemic in a “virgin” population. *Am. J. Epidemiol.* **142**, 233–253 (1995).
  62. H. Orliková, M. Malý, P. Lexová, H. Šebestová, R. Limberková, J. Jurzykowská, J. Kynčl, Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012. *BMC Public Health* **16**, 293 (2016).
  63. S. Gouma, S. J. M. Hahné, D. B. Gijssels, M. P. G. Koopmans, R. S. van Binnendijk, Severity of mumps disease is related to MMR vaccination status and viral shedding. *Vaccine* **34**, 1868–1873 (2016).
  64. S. Hahné, J. Whelan, R. van Binnendijk, C. Swaan, E. Fanoy, H. Boot, H. E. de Melker, Mumps vaccine effectiveness against orchitis. *Emerg. Infect. Dis.* **18**, 191–193 (2012).
  65. S. F. Dowell, B. A. Kupronis, E. R. Zell, D. K. Shay, Mortality from pneumonia in children in the United States, 1939 through 1996. *N. Engl. J. Med.* **342**, 1399–1407 (2000).
  66. R. I. Glass, P. E. Kilgore, R. C. Holman, S. Jin, J. C. Smith, P. A. Woods, M. J. Clarke, M. S. Ho, J. R. Gentsch, The epidemiology of rotavirus diarrhea in the United States: Surveillance and estimates of disease burden. *J. Infect. Dis.* **174**, S5–S11 (1996).
  67. J. H. Diliberti, C. R. Jackson, Long-term trends in childhood infectious disease mortality rates. *Am. J. Public Health* **89**, 1883–1885 (1999).
  68. M. J. Mina, C. J. E. Metcalf, R. L. de Swart, A. D. M. E. Osterhaus, B. T. Grenfell, Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science* **348**, 694–699 (2015).
  69. B. Sherry, Z. Mei, K. S. Scanlon, A. H. Mokdad, L. M. Grummer-Strawn, Trends in state-specific prevalence of overweight and underweight in 2- through 4-year-old children from low-income families from 1989 through 2000. *Arch. Pediatr. Adolesc. Med.* **158**, 1116–1124 (2004).
  70. R. Yip, N. J. Binkin, L. Fleshood, F. L. Trowbridge, Declining prevalence of anemia among low-income children in the United States. *JAMA* **258**, 1619–1623 (1987).

71. P. Rohani, X. Zhong, A. A. King, Contact network structure explains the changing epidemiology of pertussis. *Science* **330**, 982–985 (2010).
72. H. Broutin, C. Viboud, B. T. Grenfell, M. A. Miller, P. Rohani, Impact of vaccination and birth rate on the epidemiology of pertussis: A comparative study in 64 countries. *Proc. Biol. Sci.* **277**, 3239–3245 (2010).
73. O. N. Bjørnstad, B. F. Finkenstädt, B. T. Grenfell, Dynamics of measles epidemics: Estimating scaling of transmission rates using a time series SIR model. *Ecol. Monogr.* **72**, 169–184 (2002).
74. M. Wharton, S. L. Cochi, R. H. Hutcheson, J. M. Bistowish, W. Schaffner, W. Schaffner, A large outbreak of mumps in the postvaccine era. *J. Infect. Dis.* **158**, 1253–1260 (1988).
75. Centers for Disease Control and Prevention (CDC), Update: Mumps activity—United States, January 1–October 7, 2006. *Morb. Mortal. Wkly. Rep.* **55**, 1152–1153 (2006).
76. D. T. Gillespie, Exact stochastic simulation of coupled chemical reactions. *J. Phys. Chem.* **81**, 2340–2361 (1977).
77. E. Leuridan, P. van Damme, Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. *Vaccine* **25**, 6296–6304 (2007).
78. B. Christenson, M. Böttiger, Measles antibody: Comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. *Vaccine* **12**, 129–133 (1994).
79. B. Christenson, M. Böttiger, Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. *Vaccine* **12**, 41–45 (1994).
80. S. A. Plotkin, Correlates of protection induced by vaccination. *Clin. Vaccine Immunol.* **17**, 1055–1065 (2010).
81. W. W. Williams, P.-J. Lu, A. O'Halloran, C. B. Bridges, D. K. Kim, T. Pilishvili, C. M. Hales, L. E. Markowitz, Vaccination coverage among adults, excluding influenza vaccination – United States, 2013. *Morb. Mortal. Wkly. Rep.* **64**, 95–102 (2015).

**Acknowledgments:** We thank L. Li, S. Cobey, P. Sabeti, S. Wohl, N. Yozwiak, G. Armstrong, and M. Lipsitch for input. **Funding:** This work was supported by National Institute of General Medical Sciences award U54GM088558 (to J.A.L.) and a Doris Duke Charitable Foundation Clinical Scientist Development Award (to Y.H.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the NIH. **Author contributions:** J.A.L. and Y.H.G. conceived the study, J.A.L. performed the analyses with input and discussion from Y.H.G., and J.A.L. drafted and Y.H.G. edited the manuscript. **Competing interests:** J.A.L. has received grant funding from Pfizer to Harvard University, and previous consulting for Pfizer, for work unrelated to this analysis. Y.H.G. discloses consulting for GlaxoSmithKline for work unrelated to this analysis. **Data and materials availability:** Code for replicating analyses and figures is available at <http://github.com/joelewnard/mumps>.

Submitted 7 August 2017  
 Accepted 10 November 2017  
 Published 21 March 2018  
 10.1126/scitranslmed.aao5945

**Citation:** J. A. Lewnard, Y. H. Grad, Vaccine waning and mumps re-emergence in the United States. *Sci. Transl. Med.* **10**, eaao5945 (2018).

## Vaccine waning and mumps re-emergence in the United States

Joseph A. Lewnard and Yonatan H. Grad

*Sci Transl Med* **10**, eaao5945.  
DOI: 10.1126/scitranslmed.aao5945

### The mystery of mumps resurgence

Rising mumps cases in vaccinated populations in the United States over the past decade have raised doubts about mumps vaccine efficacy. Here, Lewnard *et al.* examined these outbreaks using mumps vaccine effectiveness data and dynamic transmission modeling. They found that the increase in mumps cases is more consistent with loss of vaccine protection over time, rather than incomplete protection against an evolving virus population or lack of immune response to the vaccine. Their work also suggested that a third vaccine dose may extend protection, which could prove useful in designing a clinical action plan to prevent the spread of mumps.

#### ARTICLE TOOLS

<http://stm.sciencemag.org/content/10/433/eaao5945>

#### SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2018/03/19/10.433.eaao5945.DC1>

#### RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/9/383/eaaf6786.full>  
<http://stm.sciencemag.org/content/scitransmed/9/421/eaaf6984.full>  
<http://stm.sciencemag.org/content/scitransmed/9/420/eaao4163.full>  
<http://stm.sciencemag.org/content/scitransmed/7/307/307ra154.full>  
<http://stm.sciencemag.org/content/scitransmed/10/441/eaaj2345.full>  
<http://stm.sciencemag.org/content/scitransmed/10/449/eaao4496.full>  
<http://science.sciencemag.org/content/sci/363/6428/677.full>  
<http://science.sciencemag.org/content/sci/363/6429/795.full>  
<http://science.sciencemag.org/content/sci/363/6431/1024.full>  
<http://science.sciencemag.org/content/sci/364/6440/584.full>  
<http://stm.sciencemag.org/content/scitransmed/11/505/eaav6419.full>  
<http://science.sciencemag.org/content/sci/366/6465/560.full>  
<http://science.sciencemag.org/content/sci/367/6473/11.full>  
<http://stm.sciencemag.org/content/scitransmed/12/528/eaax4144.full>  
<http://science.sciencemag.org/content/sci/366/6465/599.full>  
<http://science.sciencemag.org/content/sci/368/6487/116.full>  
<http://science.sciencemag.org/content/sci/368/6492/699.full>  
<http://science.sciencemag.org/content/sci/368/6497/1310.full>  
<http://science.sciencemag.org/content/sci/368/6497/1367.full>

#### REFERENCES

This article cites 79 articles, 9 of which you can access for free  
<http://stm.sciencemag.org/content/10/433/eaao5945#BIBL>

Use of this article is subject to the [Terms of Service](#)

---

*Science Translational Medicine* (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

---

*Science Translational Medicine* (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works